Beyond antibiotics

July 2024
Bioshares Fremantle




Disclaimer

This presentation contains “forward-looking statements” that are subject to risks and uncertainties. Such statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from the statements in this presentation. Actual results could differ materially depending on factors such as the availability of resources, the results of preclinical and clinical studies, the timing and effects of regulatory actions, the strength of competition and the effectiveness of patent protection. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation is limited to persons to whom offers may be made that do not need a regulated disclosure document under the corporations law. This information is provided to you for the purpose of considering such an offer and should not be circulated to any other person.

This presentation has been prepared by and issued by Neolixir Ltd ACN 654 969 310 (“company“ or “Lixa”). It should not be considered as an offer or invitation to invest in the company or as an inducement to make an offer or invitation with respect to investing in the company. No agreement to offer funds to invest in the company will be entered into on the basis of this presentation. Any offer, when made will be an offer that, under section 708(8) of the corporations act, does not need a regulated disclosure document.

You should refrain from acting or not act in reliance on this presentation material. This overview of the company does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of the company’s prospects. You should conduct your own investigation and perform your own analysis in order to satisfy yourself as to the accuracy and completeness of the information, statements and opinions contained in this presentation and making any investment decision.

Antibiotics: A broken business model

By 2050, Antimicrobial Resistance (AMR) is forecast to cause 10m deaths and US$100t economic loss per year[1]

80% of the US$71B[2] antibiotics market are off-patent, generic drugs[3] – highly unusual in pharma

Patented antibiotics are expensive (e.g. AU$250k/patient), cost >AU$1.5b[4] to develop and then get shelved as “last resort” to avoid new superbugs

New antibiotics have not solved AMR

Obviously, it's time for an entirely different approach

1. Tackling drug-resistant infections globally. The Review on Antimicrobial Resistance Chaired by Jim O’Neill. (2016).
2. Size of Global Antibiotics Market
3. Kållberg et al. 2021
4. A new class of antibiotics is cause for cautious celebration — but the economics must be fixed. Nature - 2024

Our solution NeoX™: Universal Antibiotic Resistance Breakers (uARBs)

Water-soluble, small molecules that

- tame extensively drug-resistant (XDR) bacteria
- restore antibiotic efficacy

Novel, non-antibiotic, universal Mode of Action
(505b2 lead drug + NCE at preclinical)

Host anti-inflammatory efficacy

Scalable, cost-effective companion to first-line antibiotics

Blockbuster potential in US$71B global antibiotics market



NeoX™ is FAST and UNIVERSALLY effective in extremely resistant bacteria

From “untreatable” to treatable below clinical Abx breakpoint

Including MRSA, Pseudomonas, ESKAPE, XDR I in vitro)

1 oral dose = 70% enhanced sepsis survival

Colistin-resistant E. coli (in vivo)

100% protection against lethal gut inflammation

Handles even “incurable” biofilm colonies

which are >1000x more resistant

SAFE for humans in oral, IV or topical formulations

Lead candidate is a 505b2



Example of NeoX™ making a generic antibiotic work again in resistant Pseudomonas aeruginosa biofilm colonies

First human health focus: Respiratory infection



insmed

May '24 | Positive Phase 3 clinical results for Insmed lung drug, resulting in doubling of share price adding **AU$4.5b** to market cap

https://www.biopharmadive.com/news/insmed-aspen-brensocatib-bronchiectasis-trial-results/717222/

Lixa has >5-10x value inflection potential in next 12 months*

*upon positive trial results based on peer company performance

Timeline	Completed	Series A Aug '24	24/25	Series B	25/26	Series C	2028

Roche, Meiji and Fedora join forces to tackle increasing bacterial resistance to antibiotics – FedoraPharma.com

GPN Vaccines Closes Oversubscribed AUD $18 million Series B1S

Bacterial problems are universal, and so is NeoX™

Platform technology traction across industries

Human Health

Any bacterial infection | peak sales potential >AU$6b

FDA Breakthrough by '25
Ongoing Pharma discussions (upfront, milestone $$ & royalties)

Agribusiness & industrial

Companion animals, antibiotic-free livestock, crops, fouling

Grant received
Advanced partnering

Consumer products

Over the counter (OTC), cosmetics

Near-term revenue

✓ ***In negotiation with multinational***

Our Team – Experienced biotech business builders

Maud Eijkenboom, PhD

Board

- **Managing Director, Founder**
- 30 years Life Sciences business building
- Mother of a child with AMR health concerns.

Martin Bennett

Board

- **Chairman, Legal**
- Founder & owner of Bennett Law
- Exceptional international commercial litigation, negotiation & dispute resolution

Craig Ridley

Board

- **CFO**
- Fellow Chartered Accountant
- >35 year accounting and business advisory

Prof Paul Rolan, MD

Clinical

- **CMO**
- Clinical Pharmacologist
- (consultant, >800 trials)

Andrew Barker, PhD

Science

- **CSO**
- 35 Years Biotech and Medtech R&D executive
- Successful product development with numerous acquisitions and licenses

Kristen Houston

Clinical

- **Strategic Projects**
- Senior Project Manager and BD professional
- Innovation & operational management

Virginia Castro

Quality

- **Quality and Compliance Manager**
- Pharmacist and Biochemist
- 10+ years Regulatory Affairs and Quality Assurance.

R&D Team

Dr Matthew Wee-Peng Poh
Dr Bikash Manandhar
Ethan Haese
Kathryn Green
Cathy Abberton

Partners

The University of Western Australia
CERI
J-BRIDGE
Centre for Environmental and Agricultural Solutions to Antimicrobial Resistance
Mila

In summary

Simply solving a **global crisis**

- **Short-term 5-10X** inflection potential
- **Blockbuster** potential entering clinical trials
- **Joint Development Agreement** in negotiation
- **Multi-industry** licensing & risk mitigation model
- **Experienced team**

Use of funds	
Clinical trial Phase 1	AU$1m (bridge funding)
Phase 2a	AU$3m
Manufacturing upgrade	AU$1m
Phase 2b	AU$5m
Multi-industry R&D + patent portfolio expansion	AU$2m

Current Cap table Investor class	# investors	% Holding
Management	2	29.82
University	1	6.58
Private investors	22	63.60
Total	**25**	**100**

Bonus

- AU tax credit
- >$2b global AMR non-dilutive grant opportunities

Awards

- *Bio Convention Startup Stadium finalist, San Diego, June 2024*
- *Innovator of the Year, well Being, Western Australia 2022*
- *As seen on Channel 9 & Channel 7*

Expression of interest to:
Maud Eijkenboom, PhD
Managing Director
maud@lixa.life
+61 413 668 531
Australia

Lixa
Opening the door to world health
for anyone, anything and anywhere
www.lixa.life

INVESTMENT RISKS

The information in this presentation relates to futures events, business performance and financial projections. Such forward-looking statements are only predictions and the future success of Lixa (Neolixir) in successfully developing and commercialising our technologies and products and achieving the results may differ substantially from those discussed due to the speculative nature of the investment, project-specific risks and other general risks. Investors should read any future prospectus in detail and consider the risks, assumptions and other uncertainties described before making an investment decision. Major project-specific risks related to the Lixa opportunity include, but are not limited to, the risks described below and other risk factors beyond our control.

Scientific risk that our methods are not accepted by the scientific community.

Technology risks where our human therapeutic resistance mitigation technology is at a preclinical stage of development and requires significant research, development and testing before advancing to market approval, and there remains uncertainty that our technology will meet the requirements of our future industry partners and regulatory authorities. This risk is less for Industrial, Marine, Agriculture & Food, Animal Health and Personal Care product opportunities given the lower regulatory hurdles. Further, the human health technology risks are minimised compared to other projects by publicly available data on safety and pharmacokinetics of our lead development candidate.

Product development risks of a delay in achieving future safety or efficacy milestones in clinical trials or failing to clinically validate our product due to e.g. an inability to recruit enough patients, or that our products may harm patients or may not work as well as expected may have a negative impact on the cost, speed of development or future approval of our product. Our multi-partner commercialisation strategy intends to share this risk with multinational commercial partners.

Manufacturing risks where human therapeutic products must be manufactured for clinical trials and commercial sale using a cGMP compliant manufacturing process to assure the safety and quality of our products, and any unforeseen scientific difficulties in scale-up of our production process or any quality issues during production may result in our product not being cost-effective, insufficient volumes being available to meet demand, or the product not being released, recalled or rejected.

Financing risk where the Company has limited financial resources and may need to raise additional funds from time to time to fund ongoing product development & working capital, and there is no guarantee that the Company will be able to secure sufficient funding from grants, strategic collaborations, public or private equity raisings or debt financings or other financing sources on acceptable terms, when required or at all.

Personnel risk of being unable to attract or retain the services of key employees or consultants whose knowledge is essential to the research, development and commercialisation of our products.

Partnering risk where our success will depend upon our ability to market and license our intellectual property rights and find willing and able commercial partners for the ongoing clinical development and commercialisation of the product.

Regulatory risk of not meeting the specific regulatory requirements for medicine products, marine anti-foul, animal health, agricultural and others through relevant regulatory authorities in key markets globally (US, EU, Australia, Japan, China) and other regulators where we wish to commercially market our products, which may result in delayed market approvals or not achieving registration for our product that may inhibit full commercialisation.

Intellectual Property (IP) risks where IP is a key asset of the project and its commercial value is legally protected through various intellectual property rights (IPRs) that if we fail to secure patents or other IPRs for our inventions in key jurisdictions, or if our patent claims are not sufficient to protect essential aspects of our technology, or if our patents infringe another parties patent rights, or if litigation is required to enforce our IPRs, or if there is a potential successful legal challenge to our patents will significantly impact our competitive position and performance.

Competitive risks related to new entrants developing superior technologies to our technology, and competitors with greater resources developing and reaching the market faster with better products that are more effective, easier to use or affordable than our product.

Market risks related to initial adoption and ongoing market acceptance of our product by clinicians and patients.

Reimbursement risks where the availability and amount of reimbursement for patients' medical expenses by public and private payers including government agencies, private health insurers and other healthcare payers is critical to market access, and any delay or inability to gain adequate coverage and a full reimbursement price for our product will limit future market acceptance and commercial success.

Product liability risks where the testing, marketing and sale of our products may involve product liability claims being brought against the organisation for which we will seek to limit our liability through appropriate contracts, indemnifications and product liability insurance that if we cannot obtain at an acceptable cost may prevent or inhibit the commercialisation of our products.

NeoX™ | The Marine Antifouling Opportunity

Biofilm growth on surfaces are the foundational layer that enables fouling to attach.

Biofouling on ships hulls and industrial equipment causes:

62.5%
Increased fuel consumption

55%
More greenhouse gas emissions

US$117B
Annual economic cost[3]

1. Investigation of fuel consumption on an operating ship due to biofouling growth and quality of antifouling coating, M L Hakim et al 2019 IOP Conf. Ser.: Earth Environ. Sci. 339 012037
2. Impact of Ships' Biofouling on Greenhouse Gas Emissions, Glofouling 2022
3. **Economic significance of biofilms: a multidisciplinary and cross-sectoral challenge, 2022**

NeoX™ can be integrated into new or existing coating or wash formulations* to prevent fouling and break resistance.

- ✓ **Non-biocidal and non-antibiotic**
- ✓ **Natural small molecule**
- ✓ **Cost effective and scalable**
- ✓ **Biodegradable and nontoxic**

*Upon further formulation development and proof of concept studies

Beyond antibiotics

July 2024
Bioshares Fremantle




Disclaimer

This presentation contains “forward-looking statements” that are subject to risks and uncertainties. Such statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from the statements in this presentation. Actual results could differ materially depending on factors such as the availability of resources, the results of preclinical and clinical studies, the timing and effects of regulatory actions, the strength of competition and the effectiveness of patent protection. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation is limited to persons to whom offers may be made that do not need a regulated disclosure document under the corporations law. This information is provided to you for the purpose of considering such an offer and should not be circulated to any other person.

This presentation has been prepared by and issued by Neolixir Ltd ACN 654 969 310 (“company“ or “Lixa”). It should not be considered as an offer or invitation to invest in the company or as an inducement to make an offer or invitation with respect to investing in the company. No agreement to offer funds to invest in the company will be entered into on the basis of this presentation. Any offer, when made will be an offer that, under section 708(8) of the corporations act, does not need a regulated disclosure document.

You should refrain from acting or not act in reliance on this presentation material. This overview of the company does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of the company’s prospects. You should conduct your own investigation and perform your own analysis in order to satisfy yourself as to the accuracy and completeness of the information, statements and opinions contained in this presentation and making any investment decision.

Antibiotics: A broken business model

By 2050, Antimicrobial Resistance (AMR) is forecast to cause 10m deaths and US$100t economic loss per year[1]

80% of the US$71B[2] antibiotics market are off-patent, generic drugs[3] – highly unusual in pharma

Patented antibiotics are expensive (e.g. AU$250k/patient), cost >AU$1.5b[4] to develop and then get shelved as “last resort” to avoid new superbugs

New antibiotics have not solved AMR

Obviously, it's time for an entirely different approach

1. Tackling drug-resistant infections globally. The Review on Antimicrobial Resistance Chaired by Jim O’Neill. (2016).
2. Size of Global Antibiotics Market
3. Kållberg et al. 2021
4. A new class of antibiotics is cause for cautious celebration — but the economics must be fixed. Nature - 2024

Our solution NeoX™: Universal Antibiotic Resistance Breakers (uARBs)

Water-soluble, small molecules that

- tame extensively drug-resistant (XDR) bacteria
- restore antibiotic efficacy

Novel, non-antibiotic, universal Mode of Action
(505b2 lead drug + NCE at preclinical)

Host anti-inflammatory efficacy

Scalable, cost-effective companion to first-line antibiotics

Blockbuster potential in US$71B global antibiotics market



NeoX™ is FAST and UNIVERSALLY effective in extremely resistant bacteria

From “untreatable” to treatable below clinical Abx breakpoint

Including MRSA, Pseudomonas, ESKAPE, XDR I in vitro)

1 oral dose = 70% enhanced sepsis survival

Colistin-resistant E. coli (in vivo)

100% protection against lethal gut inflammation

Handles even “incurable” biofilm colonies

which are >1000x more resistant

SAFE for humans in oral, IV or topical formulations

Lead candidate is a 505b2



Example of NeoX™ making a generic antibiotic work again in resistant Pseudomonas aeruginosa biofilm colonies

First human health focus: Respiratory infection



insmed

May '24 | Positive Phase 3 clinical results for Insmed lung drug, resulting in doubling of share price adding **AU$4.5b** to market cap

https://www.biopharmadive.com/news/insmed-aspen-brensocatib-bronchiectasis-trial-results/717222/

Lixa has >5-10x value inflection potential in next 12 months*

*upon positive trial results based on peer company performance

Timeline	Completed	Series A Aug '24	24/25	Series B	25/26	Series C	2028

Roche, Meiji and Fedora join forces to tackle increasing bacterial resistance to antibiotics – FedoraPharma.com

GPN Vaccines Closes Oversubscribed AUD $18 million Series B1S

Bacterial problems are universal, and so is NeoX™

Platform technology traction across industries

Human Health

Any bacterial infection | peak sales potential >AU$6b

FDA Breakthrough by '25
Ongoing Pharma discussions (upfront, milestone $$ & royalties)

Agribusiness & industrial

Companion animals, antibiotic-free livestock, crops, fouling

Grant received
Advanced partnering

Consumer products

Over the counter (OTC), cosmetics

Near-term revenue

✓ ***In negotiation with multinational***

Our Team – Experienced biotech business builders

Maud Eijkenboom, PhD

Board

- **Managing Director, Founder**
- 30 years Life Sciences business building
- Mother of a child with AMR health concerns.

Martin Bennett

Board

- **Chairman, Legal**
- Founder & owner of Bennett Law
- Exceptional international commercial litigation, negotiation & dispute resolution

Craig Ridley

Board

- **CFO**
- Fellow Chartered Accountant
- >35 year accounting and business advisory

Prof Paul Rolan, MD

Clinical

- **CMO**
- Clinical Pharmacologist
- (consultant, >800 trials)

Andrew Barker, PhD

Science

- **CSO**
- 35 Years Biotech and Medtech R&D executive
- Successful product development with numerous acquisitions and licenses

Kristen Houston

Clinical

- **Strategic Projects**
- Senior Project Manager and BD professional
- Innovation & operational management

Virginia Castro

Quality

- **Quality and Compliance Manager**
- Pharmacist and Biochemist
- 10+ years Regulatory Affairs and Quality Assurance.

R&D Team

Dr Matthew Wee-Peng Poh
Dr Bikash Manandhar
Ethan Haese
Kathryn Green
Cathy Abberton

Partners

The University of Western Australia
CERI
J-BRIDGE
Centre for Environmental and Agricultural Solutions to Antimicrobial Resistance
Mila

In summary

Simply solving a **global crisis**

- **Short-term 5-10X** inflection potential
- **Blockbuster** potential entering clinical trials
- **Joint Development Agreement** in negotiation
- **Multi-industry** licensing & risk mitigation model
- **Experienced team**

Use of funds	
Clinical trial Phase 1	AU$1m (bridge funding)
Phase 2a	AU$3m
Manufacturing upgrade	AU$1m
Phase 2b	AU$5m
Multi-industry R&D + patent portfolio expansion	AU$2m

Current Cap table Investor class	# investors	% Holding
Management	2	29.82
University	1	6.58
Private investors	22	63.60
Total	**25**	**100**

Bonus

- AU tax credit
- >$2b global AMR non-dilutive grant opportunities

Awards

- *Bio Convention Startup Stadium finalist, San Diego, June 2024*
- *Innovator of the Year, well Being, Western Australia 2022*
- *As seen on Channel 9 & Channel 7*

Expression of interest to:
Maud Eijkenboom, PhD
Managing Director
maud@lixa.life
+61 413 668 531
Australia

Lixa
Opening the door to world health
for anyone, anything and anywhere
www.lixa.life

INVESTMENT RISKS

The information in this presentation relates to futures events, business performance and financial projections. Such forward-looking statements are only predictions and the future success of Lixa (Neolixir) in successfully developing and commercialising our technologies and products and achieving the results may differ substantially from those discussed due to the speculative nature of the investment, project-specific risks and other general risks. Investors should read any future prospectus in detail and consider the risks, assumptions and other uncertainties described before making an investment decision. Major project-specific risks related to the Lixa opportunity include, but are not limited to, the risks described below and other risk factors beyond our control.

Scientific risk that our methods are not accepted by the scientific community.

Technology risks where our human therapeutic resistance mitigation technology is at a preclinical stage of development and requires significant research, development and testing before advancing to market approval, and there remains uncertainty that our technology will meet the requirements of our future industry partners and regulatory authorities. This risk is less for Industrial, Marine, Agriculture & Food, Animal Health and Personal Care product opportunities given the lower regulatory hurdles. Further, the human health technology risks are minimised compared to other projects by publicly available data on safety and pharmacokinetics of our lead development candidate.

Product development risks of a delay in achieving future safety or efficacy milestones in clinical trials or failing to clinically validate our product due to e.g. an inability to recruit enough patients, or that our products may harm patients or may not work as well as expected may have a negative impact on the cost, speed of development or future approval of our product. Our multi-partner commercialisation strategy intends to share this risk with multinational commercial partners.

Manufacturing risks where human therapeutic products must be manufactured for clinical trials and commercial sale using a cGMP compliant manufacturing process to assure the safety and quality of our products, and any unforeseen scientific difficulties in scale-up of our production process or any quality issues during production may result in our product not being cost-effective, insufficient volumes being available to meet demand, or the product not being released, recalled or rejected.

Financing risk where the Company has limited financial resources and may need to raise additional funds from time to time to fund ongoing product development & working capital, and there is no guarantee that the Company will be able to secure sufficient funding from grants, strategic collaborations, public or private equity raisings or debt financings or other financing sources on acceptable terms, when required or at all.

Personnel risk of being unable to attract or retain the services of key employees or consultants whose knowledge is essential to the research, development and commercialisation of our products.

Partnering risk where our success will depend upon our ability to market and license our intellectual property rights and find willing and able commercial partners for the ongoing clinical development and commercialisation of the product.

Regulatory risk of not meeting the specific regulatory requirements for medicine products, marine anti-foul, animal health, agricultural and others through relevant regulatory authorities in key markets globally (US, EU, Australia, Japan, China) and other regulators where we wish to commercially market our products, which may result in delayed market approvals or not achieving registration for our product that may inhibit full commercialisation.

Intellectual Property (IP) risks where IP is a key asset of the project and its commercial value is legally protected through various intellectual property rights (IPRs) that if we fail to secure patents or other IPRs for our inventions in key jurisdictions, or if our patent claims are not sufficient to protect essential aspects of our technology, or if our patents infringe another parties patent rights, or if litigation is required to enforce our IPRs, or if there is a potential successful legal challenge to our patents will significantly impact our competitive position and performance.

Competitive risks related to new entrants developing superior technologies to our technology, and competitors with greater resources developing and reaching the market faster with better products that are more effective, easier to use or affordable than our product.

Market risks related to initial adoption and ongoing market acceptance of our product by clinicians and patients.

Reimbursement risks where the availability and amount of reimbursement for patients' medical expenses by public and private payers including government agencies, private health insurers and other healthcare payers is critical to market access, and any delay or inability to gain adequate coverage and a full reimbursement price for our product will limit future market acceptance and commercial success.

Product liability risks where the testing, marketing and sale of our products may involve product liability claims being brought against the organisation for which we will seek to limit our liability through appropriate contracts, indemnifications and product liability insurance that if we cannot obtain at an acceptable cost may prevent or inhibit the commercialisation of our products.

NeoX™ | The Marine Antifouling Opportunity

Biofilm growth on surfaces are the foundational layer that enables fouling to attach.

Biofouling on ships hulls and industrial equipment causes:

62.5%
Increased fuel consumption

55%
More greenhouse gas emissions

US$117B
Annual economic cost[3]

1. Investigation of fuel consumption on an operating ship due to biofouling growth and quality of antifouling coating, M L Hakim et al 2019 IOP Conf. Ser.: Earth Environ. Sci. 339 012037
2. Impact of Ships' Biofouling on Greenhouse Gas Emissions, Glofouling 2022
3. **Economic significance of biofilms: a multidisciplinary and cross-sectoral challenge, 2022**

NeoX™ can be integrated into new or existing coating or wash formulations* to prevent fouling and break resistance.

- ✓ **Non-biocidal and non-antibiotic**
- ✓ **Natural small molecule**
- ✓ **Cost effective and scalable**
- ✓ **Biodegradable and nontoxic**

*Upon further formulation development and proof of concept studies